Addyi® Tablets for Hypoactive Sexual Desire Disorder

Addyi is the brand name for flibanserin, a once‑daily prescription tablet for premenopausal adults diagnosed with hypoactive sexual desire disorder. Many patients use Addyi to reduce distress from low sexual desire that is not explained by other factors. Canadian pricing with US delivery from Canada helps some households save, and cash‑pay options can support those ordering without insurance.

What Addyi® Is and How It Works

Addyi® is a centrally acting medicine approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal adults. It is not an on‑demand therapy. Flibanserin is thought to modulate neurotransmitters associated with sexual desire, including serotonin, dopamine, and norepinephrine, particularly in brain regions involved in reward and motivation.

Every CanadianInsulin order is prescription‑checked with your clinic and dispensed by a licensed Canadian pharmacy.

By dosing at bedtime, the regimen aims to minimize daytime drowsiness. Alcohol and certain interacting medicines can markedly increase the risk of low blood pressure and fainting; careful avoidance and prescriber guidance are essential. Addyi is not indicated for sexual performance issues, pain, or relationship problems.

Who Addyi Is For

Addyi is indicated for premenopausal adults with acquired, generalized HSDD characterized by low sexual desire that causes marked distress or interpersonal difficulties. The diagnosis should not be better explained by another medical or psychiatric condition, relationship issues, or the effects of a medication or substance.

Not indicated: men, postmenopausal adults, and individuals seeking treatment for other sexual dysfunctions. Do not use in hepatic impairment. Use is not recommended during pregnancy or while breastfeeding unless a clinician determines the benefit outweighs potential risks.

Extra caution is warranted in those with a history of fainting, low blood pressure, alcohol use, or use of sedatives. For background on the condition, see the overview of Hypoactive Sexual Desire Disorder.

Dosage and Usage

Typical dosing is 100 mg by mouth once nightly at bedtime. Swallow the tablet whole with water. Taking at bedtime helps reduce the impact of dizziness or sleepiness. Do not take Addyi on the same night as alcohol consumption or alongside interacting drugs. If there is no improvement after 8 weeks, clinicians often discontinue therapy.

Driving or operating machinery the next morning may be unsafe if residual drowsiness or dizziness occurs.

Strengths and Forms

Addyi is supplied as oral tablets. A commonly available strength is 100 mg. Availability can vary by dispensing pharmacy and region.

Missed Dose and Timing

If a bedtime dose is missed, skip it and take the next dose at the usual bedtime the following night. Do not take a double dose. Addyi is not intended for on‑demand use before sexual activity.

Storage and Travel Basics

Store tablets at room temperature in a dry place, away from excessive heat and moisture, and in the original, child‑resistant container. When traveling, keep the prescription label with the medicine, pack it in carry‑on luggage, and bring enough for the full trip. Temperature‑sensitive items ship with cold‑chain handling and insulated packaging, though Addyi itself is not typically temperature‑sensitive.

Benefits

Potential label‑aligned benefits include:

• Improved sexual desire in some premenopausal adults with HSDD
• Reduced distress associated with low sexual desire
• Daily dosing that is independent of timing of sexual activity

Responses vary. Clinical improvement may be gradual. If insufficient benefit is seen after a reasonable trial, prescribers frequently reassess diagnosis, contributors, and therapy.

Side Effects and Safety

• Dizziness or lightheadedness
• Sleepiness or fatigue
• Nausea
• Insomnia
• Dry mouth
• Headache

Serious effects can include significant hypotension and syncope, especially when combined with alcohol or interacting medicines. Rarely, mood changes or allergic reactions occur. Stop therapy and seek medical care if severe dizziness, fainting, trouble breathing, hives, or swelling occur.

Alcohol increases the risk of low blood pressure and fainting with Addyi. Discuss alcohol use with a clinician and avoid taking Addyi on any night alcohol is consumed.

Drug Interactions and Cautions

Flibanserin is metabolized primarily by CYP3A4, and exposure rises with inhibitors of this pathway. Avoid combining Addyi with moderate or strong CYP3A4 inhibitors such as azole antifungals or certain antidepressants. Examples include:

• Strong azole antifungals like Ketoconazole and Fluconazole
• Selective serotonin reuptake inhibitor fluvoxamine: Fluvoxamine

Other cautions:

• Grapefruit or grapefruit juice may increase exposure; avoidance is typically advised.
• CNS depressants and sedatives can increase drowsiness or dizziness. Examples include certain antihistamines, opioids, and agents such as Gabapentin or Amitriptyline.
• Antihypertensives and nitrates may compound blood pressure‑lowering effects.
• Do not use with hepatic impairment.

Always provide a full medication list, including over‑the‑counter products and supplements, to the prescribing clinician.

What to Expect Over Time

Addyi is intended for nightly use. Some individuals notice changes in desire and reduced distress over weeks. Benefit varies. If no clear improvement is observed after about 8 weeks, clinicians often consider discontinuation and alternative strategies.

Compare With Alternatives

An FDA‑approved alternative for premenopausal HSDD is bremelanotide (Vyleesi), administered as an on‑demand subcutaneous injection. Non‑pharmacological options, including counseling and addressing contributing medications or medical conditions, also play an important role. Explore the condition category for options and updates: Hypoactive Sexual Desire Disorder and the related category Hypoactive Sexual Desire Disorder Hsdd.

Pricing and Access

Ordering through CanadianInsulin provides access to Canadian pricing with US shipping from Canada. Many customers see cash‑pay savings compared with typical U.S. retail. Add Addyi to cart, upload a valid prescription, and choose prompt, express, cold‑chain shipping. If seeking extra value, see current See Promotions. Addyi can be requested and purchased without insurance if paying out of pocket.

Availability and Substitutions

Availability can vary by dispensing pharmacy. If Addyi is unavailable, a prescriber may recommend a suitable alternative or adjust therapy based on the clinical picture. No restock timelines are provided.

Patient Suitability and Cost‑Saving Tips

• Best suited for premenopausal adults with confirmed HSDD after evaluation of contributing factors.
• Not for men, not for postmenopausal adults, and not for other sexual dysfunctions.
• Avoid alcohol around the time of dosing and discuss alcohol use with a clinician.
• Provide an up‑to‑date medication list to screen for CYP3A4 inhibitors and sedatives.
• Consider a multi‑month supply to reduce per‑fill fees and simplify travel.
• Set refill reminders so you can place your order before running out.
• Use secure storage at home and pack the original labeled bottle for travel.

Questions to Ask Your Clinician

• Does my history fit acquired, generalized HSDD, and are other causes addressed?
• Is Addyi appropriate given my medicines, alcohol use, and health conditions?
• What signs of benefit should be tracked over the first 8 weeks?
• How should alcohol be handled on days when Addyi is prescribed?
• Which medicines, supplements, or foods should be avoided?
• What plan do we have if Addyi is ineffective or not tolerated?

Authoritative Sources

• Addyi official site
• MedlinePlus: Flibanserin

Ready to request your prescription fill? CanadianInsulin offers prompt, express, cold‑chain shipping from licensed Canadian pharmacies to the U.S., with friendly support for ordering and storage questions.

Disclaimer: This information is not a substitute for professional medical advice. Always follow your prescriber’s instructions and the approved product label.